FDA approves immunotherapy tablet to gradually reduce grass allergies

Global News

WHITEHOUSE STATION, N.J. – Merck & Co. says the Food and Drug Administration has approved its new tablet for grass allergies, Grastek, for patients five to 65 years old.

Meant as an alternative to weekly allergy shots, the tablet dissolves under the tongue. Taken daily for a few years, it gradually reduces sensitivity to common grasses, instead of temporarily relieving symptoms including sneezing, runny nose, and itchy, watery eyes.

Merck, based in Whitehouse Station, N.J., will market the tablet in North America. Its partner, ALK-Abello, sells it in Europe as Grazas.

Merck said Grastek will be available in U.S. pharmacies in late April. However, it’s best to start taking it three months before grass pollen season begins.

The drug can cause severe allergic reactions and shouldn’t be used by patients with severe asthma.

View original post

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s